Core Viewpoint - The article discusses the advancements in early detection of Alzheimer's disease (AD) through blood tests, highlighting the approval of new diagnostic tools that could significantly improve screening and monitoring for the disease [3][4]. Group 1: Blood Test Approvals and Developments - Roche Diagnostics received approval for its Alzheimer's blood test reagent in Hainan Province, China, which will be used clinically to exclude Alzheimer's-related amyloid pathology [3]. - The FDA approved Roche's blood test for use in primary care settings, achieving a diagnostic accuracy of 97.9% in a clinical trial involving 312 participants [3]. - Fujirebio's Alzheimer's blood test also received FDA approval and plans to enter the Chinese market in collaboration with partners [3]. Group 2: Importance of Early Detection - Alzheimer's disease accounts for 60% to 80% of all dementia cases globally, making early diagnosis crucial for effective treatment [5]. - The new blood testing methods are expected to facilitate early diagnosis and screening, allowing patients to receive treatment sooner [5]. - Traditional diagnostic methods, such as lumbar punctures and PET scans, are expensive and uncomfortable, presenting challenges for widespread clinical testing [5]. Group 3: Clinical Applications and Guidelines - Blood biomarkers for Alzheimer's have two main clinical uses: as a triage tool to determine the need for further testing and for direct pathological identification of amyloid proteins [6]. - The sensitivity and specificity thresholds for blood biomarkers are set at 90% and 75% respectively for triage testing, and both must exceed 90% for direct pathological identification [6]. - Despite the approval of several blood tests, they cannot yet serve as standalone diagnostic tools for Alzheimer's disease [6].

Core Viewpoint - The adoption of blood testing methods for Alzheimer's disease (AD) will facilitate early diagnosis and screening, allowing patients to receive treatment sooner. Current AD drugs on the market are effective only for early-stage patients [1][4]. Group 1: Blood Testing Developments - Roche Diagnostics' blood test for Alzheimer's disease has received approval from the Hainan Provincial Drug Administration for clinical use, achieving a diagnostic accuracy of 97.9% in a trial involving 312 participants [3]. - Fujirebio's blood test for Alzheimer's disease was also approved by the FDA in May 2022, with plans to introduce it to China in collaboration with partners [3]. - BGI's Alzheimer's blood test product is expected to receive approval from Chinese regulatory authorities in April 2024 and is already being promoted as an auxiliary detection tool in multiple cities [3]. Group 2: Clinical Implications and Challenges - Alzheimer's disease accounts for 60% to 80% of all dementia cases globally, highlighting the need for effective early detection methods [4]. - Traditional detection methods, such as lumbar puncture and PET scans, are expensive and uncomfortable, posing challenges for large-scale clinical testing [4]. - New blood testing methods can be combined with other diagnostic approaches, providing a cost-effective means for early screening and ongoing monitoring, especially in the elderly population [4]. Group 3: Clinical Utility of Blood Biomarkers - According to the latest guidelines from the International Alzheimer's Association, blood biomarkers serve two main clinical purposes: as a triage tool to determine the need for further PET scans or cerebrospinal fluid tests, and for direct pathological identification of amyloid proteins [5]. - A blood biomarker with sensitivity ≥90% and specificity ≥75% can be used as a triage test, while those meeting or exceeding 90% for both can replace PET imaging or cerebrospinal fluid tests for pathological identification [5]. Group 4: Current Application and Limitations - Blood testing for Alzheimer's disease is being deployed as an auxiliary method in several hospitals across China, although it cannot yet serve as an independent diagnostic criterion [6].